{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:51:59Z","timestamp":1790679119625,"version":"4.1.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The treatment of hypertension requires special attention because of comorbidities and polypharmacy. In a previous study, polypharmacy has been associated with a high risk of drug-related problems (DRPs). This study aimed to analyze DRPs in Indonesian hypertensive patients focusing on drug therapy effectiveness and adverse drug reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A cross-sectional study was conducted using medical records' data, prescriptions, and nursing records to observe DRPs that occurred in outpatients with hypertension from February to April 2019. A total of 114 outpatients aged \u226523 years with a primary diagnosis of primary hypertension were included in this study. DRPs were reviewed based on literature, recent guidelines, and drug interaction software. Classification DRPs were done using Indonesian-translated Pharmaceutical Care Network Europe V6.02. The data obtained were analyzed using univariate descriptive analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>Of all participants, 65 (57%) outpatients were found to have DRPs related to treatment effectiveness (54 cases) and adverse drug reactions (36 cases). The primary cause of the problems was an inappropriate drug (94.14%) and dose selection (2.86%). Potential drug interactions were found high (62.14%) in the combination of an antihypertensive agent with other drugs among patients. Overprescribing drugs without clear indications, untreated indications, and subtherapeutic dosage were also reported in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>A significant percentage of outpatients being treated for hypertension experienced DRPs. The role of clinical pharmacists and physicians in monitoring drug therapy needs to be prioritized to prevent and resolve DRPs in outpatients with hypertension.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jrpp.jrpp_20_16","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T09:49:13Z","timestamp":1602150553000},"page":"140-145","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Drug-related Problems in Hypertensive Patients: A Cross-sectional Study from Indonesia"],"prefix":"10.4103","volume":"9","author":[{"given":"Larasati Arrum","family":"Kusumawardani","sequence":"first","affiliation":[{"name":"Clinical Pharmacy Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Retnosari","family":"Andrajati","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azizah","family":"Nusaibah","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"key":"R1-20250523","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"R3-20250523","first-page":"1","year":"2018","journal-title":"European Society of Cardiology. 2018 ESC\/ESH Guidelines for the Management of Arterial Hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension"},{"key":"R4-20250523","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2125.2006.02744.x","article-title":"Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems","volume":"63","author":"Viktil","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"R5-20250523","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12877-020-1413-7","article-title":"Drug related problems in admitted geriatric patients: The impact of clinical pharmacist interventions","volume":"20","author":"Hailu","year":"2020","journal-title":"BMC Geriatr"},{"key":"R6-20250523","article-title":"Pharmaceutical Care Network Europe. Classification for drug related problems v6.02","year":"2010","journal-title":"Pharmaceutical Care Network Europe Foundation"},{"key":"R7-20250523","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s11096-018-0696-7","article-title":"PCNE definition of medication review: Reaching agreement","volume":"40","author":"Griese-Mammen","year":"2018","journal-title":"Int J Clin Pharm"},{"key":"R8-20250523","first-page":"1","article-title":"Assessment of drug related problems among hypertensive patients on follow up in Admaa Hospital Medical College, East Ethiopia","volume":"3","author":"Hussein","year":"2014","journal-title":"Clin Pharmol Biopharm"},{"key":"R9-20250523","first-page":"87","article-title":"Drug related problems in management of hypertensive outpatients admitted to four Indonesian primary health centers","volume":"9","author":"Nasution","year":"2016","journal-title":"Asian J Pharm Clin Res"},{"key":"R10-20250523","first-page":"36","article-title":"Problems Related to Antihypertensive Drugs in Elderly Patients at the Geriatric Clinic Dr. Soetomo Hospital, Surabaya","volume":"1","author":"Supraptia","year":"2014","journal-title":"Indones J Clin Pharm"},{"key":"R11-20250523","first-page":"1","article-title":"Drug related problems in hypertensive patients with multiple comorbidites","volume":"1","author":"Redzuan","year":"2017","journal-title":"J Pharm Res"},{"key":"R12-20250523","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1253\/circj.CJ-11-0113","article-title":"Inhibitory interaction between calcium channel blocker and clopidogrel.-Efficacy of cilostazol to overcome it-","volume":"75","author":"Lee","year":"2011","journal-title":"Circ J"},{"key":"R13-20250523","doi-asserted-by":"crossref","first-page":"81","DOI":"10.20956\/mff.v22i3.5811","article-title":"Analysis of effectiveness and side effects of using clopidogrel alone and in combination clopidogrel-aspilet in ischemic stroke patients at the RSUP Dr. Wahidin Sudirohusodo Makassar","volume":"22","author":"Inayah","year":"2018","journal-title":"Majalah Farmasi dan Farmakologi"},{"key":"R14-20250523","doi-asserted-by":"crossref","first-page":"61","DOI":"10.22159\/ajpcr.2017.v10s5.23098","article-title":"Analysis of potential drugs interaction on Antihypertensions drugs prescription in community health center of Sukmajaya district in period of June-November 2015","volume":"10","author":"Puspitasari","year":"2017","journal-title":"Asian J Pharm Clin Res"},{"key":"R15-20250523","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1136\/bmj.1.6015.942-a","article-title":"Rapid clonidine withdrawal with blood pressure overshoot exaggerated by beta-blockade","volume":"1","author":"Bailey","year":"1976","journal-title":"Br Med J"},{"key":"R16-20250523","first-page":"1061","article-title":"Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs","volume":"11","author":"Moore","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"R17-20250523","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1756283X12437358","article-title":"Overutilization of proton-pump inhibitors: What the clinician needs to know","volume":"5","author":"Heidelbaugh","year":"2012","journal-title":"Therap Adv Gastroenterol"},{"key":"R18-20250523","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/2042098617715381","article-title":"Adverse effects of proton-pump inhibitor use in older adults: A review of the evidence","volume":"8","author":"Maes","year":"2017","journal-title":"Ther Adv Drug Saf"}],"container-title":["Journal of Research in Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.JRPP_20_16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:04:43Z","timestamp":1787774683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.JRPP_20_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.4103\/jrpp.jrpp_20_16","relation":{},"ISSN":["2319-9644","2279-042X"],"issn-type":[{"value":"2319-9644","type":"print"},{"value":"2279-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"2020-02-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}